Thomas Jefferson University appoints chair of medical oncology
Click Here to Manage Email Alerts
William Kevin Kelly, DO, has been appointed chair of the department of medical oncology for Sidney Kimmel Medical College at Thomas Jefferson University.
Kelly joined Jefferson in 2010 as professor of medical oncology and urology, as well as director of the division of solid tumor oncology.
Kelly — who also serves as associate director for Sidney Kimmel Cancer Center’s clinical research organization — is recognized for his expertise in genitourinary cancers, as well as drug development for prostate cancer and other malignancies.
He helped develop the clinical response criteria for advanced prostate cancer that are used to screen novel drugs. He also led the clinical development of a novel class of histone deacetylase inhibitors, and helped launch the cancer center’s Philadelphia Prostate Cancer Biome Project, a philanthropic endeavor that supports novel prostate cancer research at Jefferson.
“Under Dr. Kelly’s leadership, [Sidney Kimmel Cancer Center’s] clinical research office has increased staff, the number of available clinical trials — including phase 1 trials — and patient accrual, and he has recruited and developed an extraordinary team of experts across the disease teams that comprise the division of solid tumor oncology,” Andrew Chapman, DO, cancer center director and executive vice president for oncology services at Jefferson Health, said in a press release. “His leadership and expertise will guide the Sidney Kimmel Cancer Center as we bring leading-edge treatment options to patients in the communities we serve, and around the world, as well as ensure that we remain a research leader as we prepare for our NCI renewal this year and beyond.”
Kelly previously served as director of the clinical management research office at Yale University and co-director of the genitourinary oncology program at Yale Cancer Center.
Collapse
Press Release
Click Here to Manage Email Alerts